By InvitationEarly Phase 1

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.

Pakistan40 participantsStarted 2025-04-01

Plain-language summary

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients presenting with greater than or equal to two warts
✓. Either gender.
✓. Age 18 - 60 years. -

Exclusion criteria

✕. Pregnant or lactating women.
✕. Patient not giving informed consent.
✕. Patient received any treatment in the last 3 months period.
✕. Patient with acute illness and immuno-suppressive disease.
✕. Patient taking immuno-suppressive drugs.
✕. Patient having hypersensitivity to any investigational medicine.
✕. Patient having cutaneous warts on face and genitals.
✕. Patient having cardiovascular disease.

What they're measuring

Size of cutaneous wart

Timeframe: 5 weeks

Trial details

NCT IDNCT06821594

SponsorJinnah Postgraduate Medical Centre

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-08-30

View on ClinicalTrials.gov More Cutaneous Warts trials